Zimmer Biomet director granted phantom stock units

Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.

Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of 154.356 Phantom Stock Units, each tied 1-for-1 to common shares. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors at a stated price of $0.0000 per unit.

Following this award, Kurdikar holds a total of 1,928.847 Phantom Stock Units. The units, including 4.508 accrued through dividend reinvestment on January 30, 2026, are scheduled to be settled in shares of Zimmer Biomet common stock within sixty days after his service as a director ends.

Insider Trade Summary

Grant/Award: 154.356 shares

Grant/Award 1 txn

Insider Kurdikar Devdatt

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units	154.356	$0.00	$0.00

Holdings After Transaction: Phantom Stock Units — 1,928.847 contracts (Direct)

Footnotes (4)

1. F1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
2. F2. The Conversion or Exercise Price of Derivative Security is 1-for-1.
3. F3. Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
4. F4. Includes 4.508 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Key Figures

Phantom units granted: 154.356 units Total phantom units after grant: 1,928.847 units Grant price: $0.0000 per unit +3 more

6 metrics

Phantom units granted 154.356 units Grant of Phantom Stock Units on March 31, 2026

Total phantom units after grant 1,928.847 units Director’s Phantom Stock Unit balance following transaction

Grant price $0.0000 per unit Stated transaction price for Phantom Stock Unit award

Conversion ratio 1-for-1 Each Phantom Stock Unit settles into one common share

Dividend reinvestment units 4.508 units Units accrued on January 30, 2026 via dividend reinvestment

Underlying security Common Stock Security delivered upon settlement of Phantom Stock Units

Key Terms

Phantom Stock Units, Deferred Compensation Plan for Non-Employee Directors, dividend reinvestment provision, settled in shares

4 terms

Phantom Stock Units financial

"The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Deferred Compensation Plan for Non-Employee Directors financial

"The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors."

dividend reinvestment provision financial

"Includes 4.508 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors."

A dividend reinvestment provision is a company policy that lets shareholders automatically use their cash dividends to buy more shares instead of receiving money. Think of it like a subscription that turns each payday into buying an extra slice of the same pie; it helps investors compound their holdings over time, often with lower transaction costs and sometimes at a small discount, which can boost long‑term returns and subtly change ownership percentages.

settled in shares financial

"Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director."

FAQ

What insider transaction did ZIMMER BIOMET (ZBH) director Devdatt Kurdikar report?

Director Devdatt Kurdikar reported receiving 154.356 Phantom Stock Units as a grant. These units were awarded under Zimmer Biomet’s Deferred Compensation Plan for Non-Employee Directors and track the value of the company’s common stock on a 1-for-1 basis.

How many Phantom Stock Units does Devdatt Kurdikar hold after this Form 4 for ZBH?

After this transaction, Devdatt Kurdikar holds 1,928.847 Phantom Stock Units. This figure includes the newly granted 154.356 units and reflects his total accumulated balance under the Zimmer Biomet non-employee director deferred compensation program.

When will Devdatt Kurdikar’s Phantom Stock Units in ZIMMER BIOMET be settled?

Kurdikar’s Phantom Stock Units are to be settled in Zimmer Biomet common stock within sixty days after his service as a director ends. Settlement converts the units into actual shares, based on a 1-for-1 conversion ratio described in the filing’s footnotes.

What is the conversion ratio for ZIMMER BIOMET (ZBH) Phantom Stock Units reported in this Form 4?

The Phantom Stock Units convert into Zimmer Biomet common stock at a 1-for-1 ratio. This means each unit will be exchanged for one share of common stock upon settlement, aligning the director’s deferred compensation directly with share performance.

How were dividend reinvestments reflected in Devdatt Kurdikar’s Phantom Stock Units at ZBH?

The filing notes that 4.508 Phantom Stock Units were accrued on January 30, 2026 through a dividend reinvestment provision. This mechanism credits additional units instead of cash when dividends are paid, increasing Kurdikar’s deferred stock-based compensation balance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kurdikar Devdatt

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW INDIANA 45680

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units(1)	$89.08(2)	03/31/2026		A		154.356		(3)	(3)	Common Stock	154.356	$0	1,928.847(4)	D

Explanation of Responses:

1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

2. The Conversion or Exercise Price of Derivative Security is 1-for-1.

3. Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

4. Includes 4.508 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed)	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)